Trial Profile
A Randomized, Double-blind, Parallel Control, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of HLX04 and Bevacizumab Combined With Oxaliplatin and Fluoropyrimidine-based Chemotherapy (XELOX or mFOLFOX6) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Henlius Biotech
- 17 Jan 2022 Planned End Date changed from 30 Apr 2021 to 30 Apr 2024.
- 20 May 2021 Status changed from active, no longer recruiting to completed, according to results published in the BioDrugs.
- 20 May 2021 Results published in the BioDrugs